BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Phase 2

Terminated

Conditions: Malignant Melanoma

Interventions: Biological: Ipilimumab

First Posted Date: 2012-09-28

Last Posted Date: 2017-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT01696045

Locations: 🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇺🇸
Childrens Hospital Of La, Los Angeles, California, United States
🇺🇸
Children'S Hospital Colorado, Aurora, Colorado, United States

and more 12 locations

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Withdrawn

Conditions: Rheumatoid Arthritis

Interventions: Drug: Orencia

First Posted Date: 2012-09-27

Last Posted Date: 2017-05-10

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01694693

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Phase 2

Completed

Conditions: Myelofibrosis

Interventions: Drug: SAR302503

First Posted Date: 2012-09-25

Last Posted Date: 2025-03-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT01692366

Locations: 🇯🇵
Investigational Site Number 392002, Bunkyo-Ku, Japan
🇯🇵
Investigational Site Number 392009, Shinjuku-Ku, Japan
🇯🇵
Investigational Site Number 392008, Shinjuku-Ku, Japan

and more 4 locations

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Phase 4

Completed

Conditions: HIV, Pediatric

Interventions: Drug: Atazanavir
Drug: Ritonavir

First Posted Date: 2012-09-25

Last Posted Date: 2018-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 108

Registration Number: NCT01691794

Locations: 🇺🇸
Children'S Medical Center Of Dallas, Dallas, Texas, United States
🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇿🇦
Local Institution, Cape Town, Western CAPE, South Africa

and more 1 locations

Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Dacarbazine

First Posted Date: 2012-09-07

Last Posted Date: 2015-06-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT01681212

Locations: 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Phase 3

Completed

Conditions: Non-Squamous Cell Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Docetaxel

First Posted Date: 2012-08-28

Last Posted Date: 2023-02-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 582

Registration Number: NCT01673867

Locations: 🇺🇸
Local Institution - 0035, Sayre, Pennsylvania, United States
🇧🇷
Local Institution - 0054, Salvador, Bahia, Brazil
🇺🇸
Local Institution - 0033, Dallas, Texas, United States

and more 84 locations

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Biological: Vemurafenib

First Posted Date: 2012-08-28

Last Posted Date: 2018-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01673854

Locations: 🇺🇸
University Hospitals Of Cleveland, Cleveland, Ohio, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 11 locations

Pattern Of Use Of Belatacept In US Transplant Recipients

Completed

Conditions: Kidney Transplantation: Transplantation, Kidney

First Posted Date: 2012-08-21

Last Posted Date: 2018-07-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5000

Registration Number: NCT01670058

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Phase 3

Completed

Conditions: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Drug: Everolimus

First Posted Date: 2012-08-20

Last Posted Date: 2022-08-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 821

Registration Number: NCT01668784

Locations: 🇫🇷
Local Institution - 0006, Vandoeuvre-lès-Nancy, Lorraine, France
🇮🇹
Local Institution - 0102, Rozzano, Italy
🇫🇷
Local Institution - 0007, Lyon Cedex, France

and more 73 locations

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Phase 2

Withdrawn

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: BMS-823778
Drug: Placebo matching with BMS-823778

First Posted Date: 2012-08-16

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01666704

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy